DGIdb - COUMARIN Drug Record

COUMARIN chembl:CHEMBL6466 Approved

Alternate Names:

LODEMA
COUMARIN
NSC-8774

Drug Info:

(0 More Sources)

Publications:

Oscarson M et al., 1998, Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase., FEBS Lett
Hadidi H et al., 1997, A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin., Food Chem Toxicol
Gao N et al., 2016, Gene polymorphisms and contents of cytochrome P450s have only limited effects on metabolic activities in human liver microsomes., Eur J Pharm Sci
Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
Li L et al., 2006, New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes., Drug Metab Dispos
Haberl M et al., 2005, Three haplotypes associated with CYP2A6 phenotypes in Caucasians., Pharmacogenet Genomics
Fukami T et al., 2005, Characterization of novel CYP2A6 polymorphic alleles (CYP2A618 and CYP2A619) that affect enzymatic activity., Drug Metab Dispos
Kiyotani K et al., 2003, Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)., Pharmacogenetics
Yoshida R et al., 2003, Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro., Clin Pharmacol Ther
Xu C et al., 2002, An in vivo pilot study characterizing the new CYP2A67, 8, and *10 alleles., Biochem Biophys Res Commun
Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun
Kitagawa K et al., 2001, CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity., J Biol Chem
Meunier V et al., 2000, Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up., Xenobiotica
Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett
Yamano S et al., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes., Biochemistry
Fukami T et al., 2005, A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity., Biochem Pharmacol
Oscarson M et al., 2002, Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity., Hum Mutat
Donato MT et al., 2000, CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers., Drug Metab Dispos
Kumondai M et al., 2018, Functional characterization of 9 CYP2A13 allelic variants by assessment of nicotine C-oxidation and coumarin 7-hydroxylation., Drug Metab Pharmacokinet
Neuhaus et al., 2001, [An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment]., Dtsch. Med. Wochenschr.
Lipps et al., 1996, Cathepsin B of Schistosoma mansoni. Purification and activation of the recombinant proenzyme secreted by Saccharomyces cerevisiae., J. Biol. Chem.
Silverstein et al., 1985, Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation., J. Biol. Chem.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Kudo et al., 1998, Evidence for modulation of osteocalcin containing gamma-carboxyglutamic acid residues synthesis by insulin-like growth factor-I and vitamin K2 in human osteosarcoma cell line MG-63., Eur. J. Endocrinol.

COUMARIN CYP2A13

Interaction Score: 5.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29342418

Sources:
PharmGKB
COUMARIN CYP2A6

Interaction Score: 4.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9827545 9409631 27339126 21521021 16679388 16041240 15900015 14583682 12844137 11779172 11394901 11278503 10923861 10544257 2322567 15993850 12325023 11038160

Sources:
PharmGKB
COUMARIN CTSB

Interaction Score: 3.43

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8576174

Sources:
NCI
COUMARIN F9

Interaction Score: 1.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11455667

Sources:
NCI
COUMARIN BGLAP

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9578515

Sources:
NCI
COUMARIN PLG

Interaction Score: 0.36

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
3160707

Sources:
NCI
COUMARIN CYP2C9

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
COUMARIN CYP2C19

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
COUMARIN CYP1A2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
COUMARIN CYP2D6

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
COUMARIN CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
COUMARIN NFE2L2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DTC: COUMARIN
- Version: 02-September-2020
Alternate Names:

CHEMBL6466 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

NCI: COUMARIN

Version: 14-September-2017

Alternate Names:

C397 NCI drug code

Drug Info:

Publications:

Silverstein et al., 1985, Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation., J. Biol. Chem.

Kudo et al., 1998, Evidence for modulation of osteocalcin containing gamma-carboxyglutamic acid residues synthesis by insulin-like growth factor-I and vitamin K2 in human osteosarcoma cell line MG-63., Eur. J. Endocrinol.

Lipps et al., 1996, Cathepsin B of Schistosoma mansoni. Purification and activation of the recombinant proenzyme secreted by Saccharomyces cerevisiae., J. Biol. Chem.

PharmGKB: coumarin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Pitarque M et al., 2001, Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity., Biochem Biophys Res Commun

Li L et al., 2006, New cytochrome P450 2D6*56 allele identified by genotype/phenotype analysis of cryopreserved human hepatocytes., Drug Metab Dispos

Oscarson M et al., 1999, Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism., FEBS Lett

ChemblDrugs: chembl:CHEMBL6466
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

COUMARIN Drug Record

COUMARIN chembl:CHEMBL6466 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29342418

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9827545 9409631 27339126 21521021 16679388 16041240 15900015 14583682 12844137 11779172 11394901 11278503 10923861 10544257 2322567 15993850 12325023 11038160

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8576174

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11455667

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9578515

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 3160707

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22931300

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

DTC: COUMARIN

Alternate Names: CHEMBL6466 ChEMBL Drug ID

Drug Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

NCI: COUMARIN

Alternate Names: C397 NCI drug code

Drug Info:

PharmGKB: coumarin

Alternate Names:

Drug Info:

ChemblDrugs: chembl:CHEMBL6466

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

n/a

PMIDs:
29342418

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9827545 9409631 27339126 21521021 16679388 16041240 15900015 14583682 12844137 11779172 11394901 11278503 10923861 10544257 2322567 15993850 12325023 11038160

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
8576174

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11455667

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9578515

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
3160707

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

CHEMBL6466 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Alternate Names:

C397 NCI drug code